Three discipline collaborative radiation therapy (3 DCRT ) special debate: I would treat all early‐stage NSCLC patients with SBRT
Year: 2019
Type: article
Abstract: Radiation Oncology is a highly multidisciplinary medical specialty, drawing significantly from three scientific disciplinesmedicine, physics, and biology.As a result, discussion of controversies or changes in practice within radiation oncology involves input from all three disciplines.For this reason, significant effort has been expended recently to foster collaborative multidisciplinary research in radiation oncology, with substantial demonstrated benefit.1,2 In light of these results, we endeavor here to adopt this team-science approach to the traditional debates featured in this journal.This article represents the second in a series of special debates entitled "Three Discipline Collaborative Radiation Therapy (3DCRT)" in which each debate team will include a radiation oncologist, medical physicist, and radiobiologist.We hope that this format will not only be engaging for the readership but will also foster further collaboration in the science and clinical practice of radiation oncology. | INTRODUCTIONStereotactic Body Radiotherapy (SBRT) has emerged as an effective treatment for early-stage inoperable Non-Small Cell Lung Cancer (NSCLC) patients.We currently have strong evidence for the safety and efficacy of SBRT for patients with tumors outside of the proximal tracheobronchial tree.As SBRT gains more widespread use, evidence is beginning to mount which not only supports the safety of SBRT for centrally located lesions, but also suggests that SBRT may be a viable alternative to surgery for operable patients.SBRT may offer the possibility of local control and long-term survival similar to surgery, but with decreased procedural morbidity, therefore improved quality of life (QoL) for such patients.However, surgery currently remains the standard of care for the treatment of resectable, early-stage NSCLC.SBRT has thus far demonstrated significant efficacy and the ability to reduce the risk of complications for some patients, but can we yet make a convincing case for SBRT as the treatment of choice for all patients with early-stage NSCLC?Arguing for the proposition will be Drs.
DOI: 10.1002/acm2.12545
Institutions: University of Maryland, Baltimore, University of Arkansas for Medical Sciences, University of California, Los Angeles, The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University, Wayne State University, The Barbara Ann Karmanos Cancer Institute
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $600
OpenAlex ID: W2916933071